Latest News
Cizzle Biotechnology secures Canadian patent for lung cancer biomarker test
4 February 2026 - Cizzle Biotechnology Holdings plc (LSE: CIZ), a UK-based developer of diagnostic tests for early-stage cancer, announce on Wednesday that it has been granted patent protection in Canada covering methods to measure the CIZ1B lung can...
Viatris names new chief legal officer
4 February 2026 - Global healthcare company Viatris Inc (Nasdaq:VTRS) announced on Tuesday the appointment of Matthew J Maletta as chief legal officer (CLO), effective 9 February 2026.This follows the transition of the company's current CLO, Bri...
Biosion reports first patient dosed in Phase 1a/1b trial of BSI-082
4 February 2026 - Biosion Inc, a China-based clinical-stage biotechnology company developing innovative antibody-based therapeutics, announced on Tuesday that the first patient has been dosed in a Phase 1a/1b Investigator-Initiated Trial (IIT) assess...
AbbVie submits FDA and EMA applications for new upadacitinib indication in NSV
4 February 2026 - US pharmaceutical company AbbVie (NYSE:ABBV) announced on Tuesday that it has submitted applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for a new indication of upadacitinib (RINVOQ; 15 m...
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
3 February 2026 - US-based clinical-stage precision medicine company Relay Therapeutics, Inc. (NASDAQ: RLAY) on Tuesday said the US Food and Drug Administration has granted Breakthrough Therapy designation to zovegalisib in combination with fulvestra...